Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM with 9% CAGR Growth, states DelveInsight

The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.

In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United Kingdom, and Japan.

JAK inhibitors remain the cornerstone of Myelofibrosis therapy, led by JAKAFI/JAKAVI (ruxolitinib), which generated close to USD 1.5 billion in revenue in 2024. Additional JAK inhibitors such as INREBIC, VONJO, and OJJAARA provide differentiated approaches by targeting multiple molecular pathways. Although JAKAFI maintains market dominance, expected patent expirations between 2027 and 2028 for Novartis and Incyte may significantly alter the competitive environment. To sustain its leadership, Incyte is investigating combination strategies to extend JAKAFI's clinical utility and commercial lifespan.

Innovative agents including imetelstat (a telomerase inhibitor), navtemadlin (an MDM2 inhibitor), and pelabresib (a BET inhibitor) are progressing through development to address unmet needs, particularly in patients with insufficient response to JAK inhibitors.

Future expansion of the market is expected to be driven by novel treatment modalities, including therapies targeting lower-risk populations, next-generation frontline and combination regimens, and drugs aimed at managing cytopenias-an area that remains a major clinical challenge.
Key companies operating in the Myelofibrosis space include Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics, Galecto Biotech AB, Actuate Therapeutics, Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others.

Access the full Myelofibrosis Market Forecast through 2034 to gain detailed insights into epidemiology trends, competitive dynamics, and emerging therapies shaping the future treatment landscape @ https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

According to DelveInsight's report, "Myelofibrosis Market Insights, Epidemiology, and Market Forecast-2034," the 7MM market is set for substantial expansion over the coming decade.

Rising Disease Burden of Myelofibrosis
Myelofibrosis is a rare hematologic malignancy characterized by abnormal blood cell production and progressive bone marrow fibrosis, which disrupts normal hematopoiesis. Common manifestations include anemia, fatigue, and splenomegaly. The disease primarily affects older adults and may occur as a primary condition or evolve from polycythemia vera or essential thrombocythemia.

In 2024, approximately 55,900 prevalent cases were reported across the 7MM (United States, EU4, UK, and Japan), with numbers projected to increase steadily through 2034. The United States represented the largest market, valued at nearly USD 1.7 billion. High-risk patients accounted for the majority of diagnosed US cases, and individuals aged 70 years and older comprised the largest age segment, with around 12,100 cases.

Download DelveInsight's comprehensive Myelofibrosis Market report to explore in-depth analysis of key drugs, late-stage pipeline assets, and growth opportunities across the 7MM @ https://www.delveinsight.com/sample-request/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Primary Drivers of Myelofibrosis Market Growth
The growing incidence of Myelofibrosis is supported by aging populations, enhanced diagnostic capabilities, improved disease awareness, and continued therapeutic innovation.

Major growth contributors include:
• Increased R&D investments focused on targeted and disease-modifying therapies
• Expanding development of biologics and immunotherapy-based strategies
• Diversification of treatment approaches beyond JAK inhibitors by targeting alternative molecular pathways

Stay ahead of market shifts in Myelofibrosis therapeutics by uncovering actionable intelligence on pricing, drug uptake, and unmet clinical needs driving investment decisions @ Myelofibrosis Drugs Market and Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myelofibrosis Market Landscape and Leading Therapies
Currently, JAKAFI/JAKAVI (ruxolitinib), developed by Incyte and Novartis, remains the standard of care, generating nearly USD 1,500 million across the 7MM in 2024 due to its effectiveness in symptom control and spleen volume reduction.

Other marketed therapies include:
• INREBIC (fedratinib) - Bristol Myers Squibb
• XPOVIO (selinexor) - Karyopharm Therapeutics
• RYTELO (imetelstat) - Geron Corporation
• REBLOZYL (luspatercept) - Bristol Myers Squibb
• Navtemadlin (KRT-232) - Kartos Therapeutics

Pipeline candidates such as Pelabresib (Novartis), Bomedemstat (Merck), TL-895 (Telios Pharma), and TP-3654 (Syntara) are advancing in late-stage trials and may provide meaningful alternatives for patients inadequately controlled on current therapies.

Myelofibrosis Companies Advancing Innovation
Numerous pharmaceutical and biotechnology firms are actively developing novel therapies. Leading participants include Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb (NYSE: BMY), Sumitomo Pharma (TSE: 4506), Keros Therapeutics (NASDAQ: KROS), Galecto Biotech AB (NASDAQ: GLTO), Actuate Therapeutics, Karyopharm Therapeutics (NASDAQ: KPTI), AbbVie (NYSE: ABBV), Sierra Oncology (Formerly NASDAQ: SRRA), and others

Their pipelines feature candidates such as LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, selinexor, navitoclax, and momelotinib, which are expected to intensify market competition and broaden treatment options.

Recent Myelofibrosis Clinical Developments
• January 2026, Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced that OPN-2853, a bromodomain and extra-terminal motif (BET) small molecule inhibitor, has been granted Orphan Drug Designation (ODD) for the treatment of myelofibrosis (MF) by the U.S. Food and Drug Administration (FDA). Additionally, the generic name of zavabresib for OPN-2853 has been approved by the International Nonproprietary Names (INN) for Pharmaceutical Substances.
• September 2025: Karyopharm completed enrollment in the Phase III SENTRY trial evaluating selinexor plus ruxolitinib in JAK inhibitor-naïve patients.
• November 2024: MorphoSys announced positive topline results from the Phase III MANIFEST-2 study of pelabresib combined with ruxolitinib.
• October 2024: Ajax Therapeutics dosed the first patient in a Phase I trial of AJ1-11095, a next-generation Type II JAK2 inhibitor.
These advancements demonstrate accelerating innovation, with several agents showing potential for disease modification and improved quality of life.

Request a sample or customization of the Myelofibrosis Market Forecast report to align strategic planning with evolving clinical, regulatory, and commercial developments @ Myelofibrosis Clinical Trials and FDA Approvals @ https://www.delveinsight.com/report-store/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myelofibrosis Epidemiology Overview
The report provides detailed epidemiological analysis across the 7MM from 2020 to 2034, including total prevalence, diagnosed cases, severity distribution, and gender trends.
In 2024, total prevalence reached approximately 55,900 cases, with steady growth anticipated. Within Europe, Germany reported the highest diagnosed cases, while the UK recorded the lowest. In the US, most patients were high-risk, and primary Myelofibrosis accounted for nearly 75% of cases. Around 60% of US patients carried JAK2 mutations, highlighting its central pathogenic role.

Myelofibrosis Market Drivers and Challenges
Myelofibrosis Market Drivers:
• Rising prevalence in aging demographics
• Continuous innovation in precision therapies
• Enhanced diagnostic access and early detection

Myelofibrosis Market Restraints:
• High treatment costs and reimbursement challenges
• Long-term adverse effects of JAK inhibitors
• Complexity in managing advanced or refractory disease
Despite these limitations, multiple Phase II and III programs continue to show encouraging clinical outcomes.

For in-depth insights into Myelofibrosis epidemiology, market projections, and emerging therapies, explore the Myelofibrosis Market Forecast @ https://www.delveinsight.com/sample-request/myelofibrosis-mf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Myelofibrosis Market Scope
• Study Period: 2020-2034
• Regions Covered: United States, EU4, United Kingdom, Japan
• Key Metrics: Market size, treatment adoption, epidemiology segmentation, therapy patterns, and pipeline assessment
• Competitive analyses include SWOT, PESTLE, Porter's Five Forces, reimbursement insights, and evaluation of unmet needs.

Analysts Commentary on Myelofibrosis Market
The Myelofibrosis market is entering a transformative phase driven by expanding therapeutic innovation and a deeper understanding of disease biology. While JAK inhibitors continue to anchor treatment, upcoming patent expirations and persistent unmet needs are creating space for next-generation agents targeting novel pathways such as BET, MDM2, and telomerase inhibition. The growing focus on cytopenia management and lower-risk patient populations reflects a strategic shift toward broader disease control rather than symptom management alone. With late-stage pipeline assets advancing and strong investment from major pharmaceutical players, competitive intensity is expected to rise, ultimately improving patient outcomes and reshaping long-term market dynamics through 2034.

Future Outlook
The Myelofibrosis market is expected to grow consistently, driven by improved awareness, molecular diagnostics, and innovative therapeutic launches. The combination of established JAK inhibitors with next-generation targeted and immunotherapy agents is likely to redefine the treatment paradigm by 2034.

With strong late-stage pipelines and sustained pharmaceutical investment, the Myelofibrosis market is positioned for dynamic expansion, enhanced therapeutic diversity, and improved patient outcomes in the coming decade.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.